Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Post-Transplantation Diabetes Mellitus
NCT03113110Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in post-transplantation diabetes mellitus (PTDM), sponsored by Medical University of Vienna. Primary endpoint: 2-hour blood glucose at 4 weeks. Started Jan 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
post-transplantation diabetes mellitus (PTDM)
Beyond the preview
Go deeper on NCT03113110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113110.